The global market for implantable pacemaker products is expected to reach $5.3bn by 2023, a CAGR of 5.1% from 2017, driven by the rising aging population and growing burden of heart disease.
The global market for implantable pacemaker products is expected to reach $5.3bn by 2023, a CAGR of 5.1% from 2017, according to "Interventional Cardiology: Implantable Pacemaker Products," a new analysis from Informa's Meddevicetracker.
The top three top competitors in the pacemaker space are Abbott Laboratories Inc., Boston Scientific Corp. and Medtronic PLC, accounting for about 84% of worldwide sales in...
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
